AUSTRALIA Trends and Developments Contributed by: Suzy Madar, Matthew Swinn, Kate Hay and Scott Bouvier, Mallesons
Infrastructure and Capital: Building Systems That Can Scale Infrastructure and capital allocation have become defining issues for Australia’s life sciences sector. Australia continues to lead early-stage research and clinical trials; however, gaps in late-stage funding, manufacturing capacity and scalable infrastructure are challenges that are becoming increasingly visible as innovation moves closer to commercial reality. Public investment remains a central driver of sec- tor development. State and federal governments are directing funding towards hospital upgrades, work- force expansion and digital health capability, with increasing emphasis on out-of-hospital care and vir- tual delivery of care. Recent state budget commit- ments, including multi-billion-dollar hospital upgrade programmes and significant workforce growth tar- gets, reflect a recognition that healthcare infrastruc- ture must support new models of care and not simply expand existing ones. National healthcare revenue is forecast to rise from approximately AUD217 billion in 2025 to over AUD250 billion by 2030 (IBISWorld, May 2025), underscoring the scale of public and private capital that is necessary to support the sector. Importantly, infrastructure investment is no longer confined to bricks and mortar. Digital enablement is increasingly recognised as core infrastructure. Elec- tronic medical records, diagnostics platforms and virtual care systems are no longer treated as discre- tionary upgrades but as foundational components of service delivery. This convergence of data, technol- ogy and regulation is rewriting how health systems operate and how risk is allocated between govern- ments, providers and technology partners. Procure- ment frameworks increasingly require demonstrable cyber-resilience, interoperability and data governance at the point of tender. While private capital remains buoyant, it is selective. Investors are prioritising assets with clear regulatory pathways, defensible intellectual property portfolios and credible commercialisation strategies. There is a discernible shift away from speculative early-stage plays towards later-stage assets and infrastructure platforms capable of scaling across jurisdictions and clinical settings. This has increased the importance
of structured funding arrangements, milestone-based investments and cross-border licensing transactions, particularly where Australian clinical data is used to support global development strategies. Mixed-use health precincts and community hubs con- tinue to attract investment, particularly where they integrate inpatient, outpatient, allied health and digi- tal services. These projects require planning approv- als, licensing regimes and workforce availability, and involve complex data-sharing obligations – all of which increasingly shape their viability. Notably, manufacturing capacity remains a critical constraint. Advanced therapeutics, biologics and personalised medicines are at the forefront of inno- vation but require specialised facilities and workforce capability that Australia is still developing at scale. Contract development and manufacturing organisa- tions are therefore playing a more prominent role, often acting as de-risking partners. These arrange- ments raise complex legal issues around long-term supply security, technology transfer, data ownership, regulatory responsibility and product liability – issues that are becoming increasingly central to life sciences transactions. Advanced Therapeutics and Technology: Innovation and Commercialisation Innovation in therapeutics and technology continues to accelerate, with Australia playing an increasingly active role in the development of advanced and pre- cision medicines. Domestic investment in biotech- nology is underpinned by funding mechanisms such as the Medical Research Future Fund (which has grown to nearly AUD25 billion and supports strategic translational and clinical projects) and targeted pro- grammes like the BioMedTech Incubator (which offers non-dilutive funding of up to several million dollars per project to help bridge discovery and early clinical development for novel therapies and platforms). At the same time, federal funding – including an AUD13.6 million investment in national clinical trials reform and infrastructure (Media Release, 2 October 2025), as well as multi-million dollar investments in heart dis- ease, diabetes and cancer clinical research streams – are strengthening Australia’s capacity to translate research into measurable patient benefit.
26 CHAMBERS.COM
Powered by FlippingBook